Mechanisms and biomarkers of cancer-associated thrombosis.

Ann S Kim, Alok A Khorana, Keith R McCrae

Translational research : the journal of laboratory and clinical medicine 2020 Nov

filter terms:

Cancer-associated thrombosis is a leading cause of non-cancer death in cancer patients and is comprised of both arterial and venous thromboembolism (VTE). There are multiple risk factors for developing VTE, including cancer type, stage, treatment, and other medical comorbidities, which suggests that the etiology of thrombosis is multifactorial. While cancer-associated thrombosis can be treated with anticoagulation, benefits of therapy must be balanced with the increased bleeding risks seen in patients with cancer. Although risk models exist for primary and recurrent VTE, additional predictors are needed to improve model performance and discrimination of high-risk patients. This review will outline the diverse mechanisms driving thrombosis in cancer patients, as well as provide an overview of biomarkers studied in thrombosis risk and important considerations when selecting candidate biomarkers. Copyright © 2020 Elsevier Inc. All rights reserved.

Citation

Ann S Kim, Alok A Khorana, Keith R McCrae. Mechanisms and biomarkers of cancer-associated thrombosis. Translational research : the journal of laboratory and clinical medicine. 2020 Nov;225:33-53